Roslin Cell Therapies Ltd was formed, following the creation of Roslin Cells Ltd, to focus on delivery of GMP contract manufacturing services. Roslin Cell Therapies Ltd continues to trade under the trade name RoslinCT.
Building on this wealth of scientific expertise, Roslin Cells Ltd was formed as a spin out from the Roslin Institute in 2006.
Roslin Cells Ltd built on the legacy of Dolly and aimed to advance the field of regenerative medicine by providing human embryonic stem cell (hESC) derivation services. By 2009, Roslin Cells Ltd had positioned itself as a pioneer in hESC derivation, differentiation and characterisation and became the first European company to successfully establish a GMP grade hESC line.
Roslin Cells Ltd also aided in the establishment of the first European Bank for induced pluripotent Stem Cells (EBiSC). The EbiSC collaboration was designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services.
In 2015, in order to focus exclusively on delivery of its GMP contract manufacturing services, Roslin Cell Therapies Ltd was formed. Roslin Cell Therapies Ltd continues to trade under the trade name RoslinCT.
Today, more than a decade after our journey began, RoslinCT is an established leader and a reliable partner for the development, optimization, scale-up and GMP manufacture of cell-based therapeutic products. We show commitment to working to the highest quality standards and provide reliable yet flexible and accommodating expert services to accelerate the route to market for our clients.